研究目的: 瀰漫性大型B細胞淋巴瘤,是最常見的非何杰金氏淋巴瘤。在台灣,瀰漫性大型B細胞淋巴瘤約佔所有淋巴瘤的30-40%。雖然有相同的病名,但表現的差異度卻很大。臨床常常使用International Prognostic Index(IPI)來評估預後,但仍無法精準的分類,所以希望有方便且準確度高的生物標誌可以預測預後。 研究方法與材料: 本研究利用microRNA表現輿圖分析結果選定5個microRNAs(微小核甘核酸),包括mir-330、mir-30d、mir-27b、mir-193、mir-214。利用即時定量聚合酶連鎖反應(real-time PCR),測量血液檢體中治療前後的miRNA的表現。本研究共分析18個病人。 研究結果: 在瀰漫性大型B細胞淋巴瘤血液樣本中,只有mir-214 (p值為<0.001)與mir-30d( p值為0.012) 的表現上比對照組有明顯的增加。mir-30d、mir-330、mir-193在治療後microRNAs表現量比治療前有統計學上差異的增加。但這5個microRNAs與IPI沒有明顯的關係。但在治療後mir-214和mir-30d在完全緩解組的表現量有比部分緩解組高的趨勢。 結論與建議: mir-30d、mir-330、mir-193可以幫忙作為預測治療效果的指標;但它們造成淋巴瘤的病理原因仍待商榷。
Purpose: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. In Taiwan, DLBCL occupied 30-40% of all lymphoma patients. DLBCL is heterogeneous in biogenesis, and differed in treatment response. We often used to take International Prognostic Index (IPI) to predict the survival, however, the IPI still couldn’t identify the outcome satisfactorily. So we want to find other biomarker to improve the prediction. Methods and Materials:In this study, 5 microRNA, including mir-330、mir-30d、mir-27b、mir-193、mir-214 were chose by previous microarray data. The expression levels of miRNA in blood sample were evaluated by real-time RT-PCR .Total 18 patients were analyzed . Results: The mir-214 and mir-30d expression levels in DLBCL patients were significantly higher than in control group(P<0.05). After-treatment, the level of mir-30d, 330 and 193b showed significantly increased compared with pre-treatment , (P<0.05). No any correlation of microRNA change and IPI score were found in our study groups. The increased level of mir-214 and mir-30d is higher in the complete remission group than in the partial remission group. Conclusion: The expression of mir-30d、mir-330、mir-193 might be used to predict the treatment response, even outcome. But the possible role of these microRNA involved in DLBCL need further study.
為了持續優化網站功能與使用者體驗,本網站將Cookies分析技術用於網站營運、分析和個人化服務之目的。
若您繼續瀏覽本網站,即表示您同意本網站使用Cookies。